GSK-256066

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-256066
Drug Alias Name256066GSK-256066
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsRhinitis, Allergic, SeasonalRhinitis, AllergicPulmonary Disease, Chronic Obstructive +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySlovakiaNetherlandsNew Zealand +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsRhinitis, Allergic, SeasonalRhinitis, AllergicPulmonary Disease, Chronic Obstructive +[4] 

Other Information

ATC CodeN/A
Related LinksN/A